Laura Francis Sells 14,957 Shares of SiBone (NASDAQ:SIBN) Stock

SiBone (NASDAQ:SIBN) CEO Laura Francis sold 14,957 shares of the stock in a transaction that occurred on Monday, May 18th. The shares were sold at an average price of $14.71, for a total transaction of $220,017.47. Following the completion of the sale, the chief executive officer directly owned 503,444 shares of the company’s stock, valued at $7,405,661.24. This trade represents a 2.89% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

SiBone Price Performance

Shares of SIBN stock opened at $14.81 on Friday. The firm has a fifty day simple moving average of $13.38 and a 200-day simple moving average of $16.10. The company has a market capitalization of $656.82 million, a PE ratio of -37.97 and a beta of 0.67. SiBone has a twelve month low of $11.48 and a twelve month high of $21.89. The company has a current ratio of 9.99, a quick ratio of 8.34 and a debt-to-equity ratio of 0.20.

SiBone (NASDAQ:SIBN) last released its quarterly earnings results on Monday, May 11th. The company reported ($0.10) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.17) by $0.07. The firm had revenue of $52.59 million for the quarter, compared to the consensus estimate of $51.16 million. SiBone had a negative net margin of 8.10% and a negative return on equity of 9.56%. Equities research analysts anticipate that SiBone will post -0.44 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

SIBN has been the subject of a number of analyst reports. Truist Financial reissued a “buy” rating and issued a $18.00 price target (down from $20.00) on shares of SiBone in a report on Tuesday, May 12th. Wall Street Zen downgraded SiBone from a “buy” rating to a “hold” rating in a report on Saturday, April 18th. Finally, TD Cowen cut their target price on SiBone from $22.00 to $18.00 and set a “buy” rating on the stock in a research report on Tuesday, May 12th. Six research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, SiBone presently has a consensus rating of “Moderate Buy” and an average target price of $23.00.

Hedge Funds Weigh In On SiBone

Several large investors have recently modified their holdings of SIBN. First Light Asset Management LLC lifted its holdings in SiBone by 162.4% during the 4th quarter. First Light Asset Management LLC now owns 5,032,904 shares of the company’s stock worth $99,249,000 after buying an additional 3,115,001 shares during the last quarter. Granahan Investment Management LLC increased its holdings in shares of SiBone by 97.6% in the 1st quarter. Granahan Investment Management LLC now owns 1,739,097 shares of the company’s stock valued at $21,965,000 after acquiring an additional 858,942 shares during the last quarter. Paradigm Capital Management Inc. NY raised its position in shares of SiBone by 113.3% during the 1st quarter. Paradigm Capital Management Inc. NY now owns 1,126,500 shares of the company’s stock valued at $14,228,000 after acquiring an additional 598,300 shares in the last quarter. Cadian Capital Management LP lifted its stake in SiBone by 96.8% during the fourth quarter. Cadian Capital Management LP now owns 1,171,100 shares of the company’s stock worth $23,094,000 after purchasing an additional 576,100 shares during the last quarter. Finally, American Century Companies Inc. lifted its stake in SiBone by 22.5% during the third quarter. American Century Companies Inc. now owns 2,838,107 shares of the company’s stock worth $41,777,000 after purchasing an additional 521,683 shares during the last quarter. Institutional investors own 98.11% of the company’s stock.

SiBone Company Profile

Si-BONE, Inc is a commercial‐stage medical device company focused on the design, development and commercialization of implant systems to treat degenerative conditions of the sacroiliac (SI) joint. Its flagship product, the iFuse Implant System, consists of triangular titanium implants that are inserted via a minimally invasive surgical procedure to stabilize the SI joint and alleviate chronic lower back and buttock pain.

FDA‐cleared in 2012, the iFuse portfolio has expanded to include the iFuse-3D and iFuse-3Di devices, which feature a porous, 3D-printed surface to promote bone ongrowth and biological fixation.